Novel markers of angiogenesis in the setting of cognitive impairment and dementia

Manuscript Number: 

19-1293R2

Author(s): 
Liana G. Apostolova, Christopher M. Callahan, Jamie Case, Sujuan Gao, Kathleen A. Lane, Shannon L. Risacher, Andrew J. Saykin, Cecily G. Swinford, Mervin C. Yoder

Disclosures

Liana G. Apostolova

  • Consulting Fees:
    Advisory board - Biogen

Christopher M. Callahan

  • Nothing to Disclose

Jamie Case

  • Nothing to Disclose

Sujuan Gao

  • Equity:
    Symbol Qty ABT 120 AMAT 100 F 100 GE 250 INTC 100 KO 200 MSFT 100 MSI 26 PFE 100 PG 50 RSG 100 TWTR 100 WFC 100 XOM 50

Kathleen A. Lane

  • Equity:
    I own no more than $10,000 in stocks such as JNJ, PG, ABT and ABBV. None of these to my knowledge had their products used. These stocks were selected by my stockbroker.

Shannon L. Risacher

  • Nothing to Disclose

Andrew J. Saykin

  • Consulting Fees:
    Arkley BioTek (joint NIH SBIR grant); Bayer Healthcare Pharmaceuticals (Scientific Advisory Board); Avid Radiopharmaceuticals (in kind contribution of PET tracer precursor); Springer-Nature Publishing (Editorial Office Support as Editor in Chief, Brain Imaging and Behavior).
    Grants
    • Agency: 
      Eli Lilly (collaborative research grant)
      Dates: 
      2016-2019

Cecily G. Swinford

  • Nothing to Disclose

Mervin C. Yoder

  • Nothing to Disclose